These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Wang MD; Xu XJ; Wang KC; Diao YK; Xu JH; Gu LH; Yao LQ; Li C; Lv GY; Yang T Cancer Sci; 2024 Jul; 115(7):2159-2169. PubMed ID: 38695305 [TBL] [Abstract][Full Text] [Related]
4. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. Tang H; Cao Y; Jian Y; Li X; Li J; Zhang W; Wan T; Liu Z; Tang W; Lu S Biosci Trends; 2022 May; 16(2):130-141. PubMed ID: 35431288 [TBL] [Abstract][Full Text] [Related]
5. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202 [TBL] [Abstract][Full Text] [Related]
6. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma. Bai J; Huang M; Song B; Luo W; Ding R Technol Cancer Res Treat; 2023; 22():15330338231159718. PubMed ID: 36855803 [TBL] [Abstract][Full Text] [Related]
7. Implication of microscopic and macroscopic vascular invasion for liver resection in patients with hepatocellular carcinoma. Faber W; Stockmann M; Kruschke JE; Denecke T; Bahra M; Seehofer D Dig Surg; 2014; 31(3):204-9. PubMed ID: 25196847 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. Guglielmi A; Ruzzenente A; Conci S; Valdegamberi A; Vitali M; Bertuzzo F; De Angelis M; Mantovani G; Iacono C World J Gastroenterol; 2014 Jun; 20(24):7525-33. PubMed ID: 24976693 [TBL] [Abstract][Full Text] [Related]
9. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Sun HC; Zhou J; Wang Z; Liu X; Xie Q; Jia W; Zhao M; Bi X; Li G; Bai X; Ji Y; Xu L; Zhu XD; Bai D; Chen Y; Chen Y; Dai C; Guo R; Guo W; Hao C; Huang T; Huang Z; Li D; Li G; Li T; Li X; Li G; Liang X; Liu J; Liu F; Lu S; Lu Z; Lv W; Mao Y; Shao G; Shi Y; Song T; Tan G; Tang Y; Tao K; Wan C; Wang G; Wang L; Wang S; Wen T; Xing B; Xiang B; Yan S; Yang D; Yin G; Yin T; Yin Z; Yu Z; Zhang B; Zhang J; Zhang S; Zhang T; Zhang Y; Zhang Y; Zhang A; Zhao H; Zhou L; Zhang W; Zhu Z; Qin S; Shen F; Cai X; Teng G; Cai J; Chen M; Li Q; Liu L; Wang W; Liang T; Dong J; Chen X; Wang X; Zheng S; Fan J; Hepatobiliary Surg Nutr; 2022 Apr; 11(2):227-252. PubMed ID: 35464283 [TBL] [Abstract][Full Text] [Related]
10. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy. Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815 [TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary Approach to the Treatment of Advanced Hepatocellular Carcinoma in the Era of New Biologic Agents. Shindoh J J Nippon Med Sch; 2022 May; 89(2):145-153. PubMed ID: 34840212 [TBL] [Abstract][Full Text] [Related]
12. Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study. Wang DD; Wu LQ; Wang ZS Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):626-632. PubMed ID: 27919852 [TBL] [Abstract][Full Text] [Related]
13. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748 [TBL] [Abstract][Full Text] [Related]
15. [The progresses of liver resection for solitary large hepatocellular carcinoma]. Yang LY Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):13-16. PubMed ID: 31902163 [TBL] [Abstract][Full Text] [Related]
16. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy? Jiang C; Sun XD; Qiu W; Chen YG; Sun DW; Lv GY Hepatobiliary Pancreat Dis Int; 2023 Feb; 22(1):7-13. PubMed ID: 36825482 [TBL] [Abstract][Full Text] [Related]
17. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. Zhang XP; Wang K; Wei XB; Li LQ; Sun HC; Wen TF; Chai ZT; Chen ZH; Shi J; Guo WX; Xie D; Cong WM; Wu MC; Lau WY; Cheng SQ Oncologist; 2019 Dec; 24(12):e1476-e1488. PubMed ID: 31138726 [TBL] [Abstract][Full Text] [Related]
18. Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate. Chen QF; Chen S; Chen M; Lyu N; Zhao M J Clin Transl Hepatol; 2024 Mar; 12(3):298-304. PubMed ID: 38426191 [TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Iwamoto H; Shimose S; Shirono T; Niizeki T; Kawaguchi T Clin Mol Hepatol; 2023 Jul; 29(3):593-604. PubMed ID: 36775834 [TBL] [Abstract][Full Text] [Related]